Amgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting

Preclinical Results for Mcl-1 Inhibitor for Multiple Myeloma Accepted as Oral Presentation New Data on Bispecific T Cell Engagers (BiTE®) Immunotherapy Platform Preclinical Study Combining Different Immuno-Oncology Agents THOUSAND OAKS, Calif., March 31, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new preclinical data from its oncology portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting from April 1-5, 2017, in Washington, D.C. These data provide insights into the potential of Amgen's half-life optimized bispecific T cell engager (BiTE®) immunotherapy platform across different cancers, as well as the local and systemic ...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news